785 articles
Antag Therapeutics reports AT7687 is well tolerated in humans and drives weight loss in primates when combined with cagrilintide.
4Moving Biotech's 4P004 targets knee osteoarthritis at the source with a joint-injected GLP-1 analog, earning FDA Fast Track status.
An oral iron-targeting drug significantly slowed Multiple System Atrophy progression in a Phase 2 trial, with Phase 3 planning underway.
ACD856 finishes repeated-dose safety testing with a wide therapeutic window, positioning it as a multi-brain-disorder candidate.
Insilico Medicine's new AI-powered Longevity Board aims to develop drugs that slow biological aging, not just treat individual diseases.
Research shows four simple behaviors — no smoking, healthy weight, daily movement, and good diet — can add 12–14 years to your life.
Regeneron's Otarmeni restores hearing in 80% of pediatric patients with OTOF gene mutations — a historic first for genetic deafness treatment.
The FDA expanded approval of teplizumab to toddlers with preclinical type 1 diabetes, potentially delaying disease onset during critical early years.
A new NCI study reveals pancreatic and lung cancers get far less research funding per death than breast and prostate cancers.
A landmark autopsy study overturns decades of assumption, revealing heart attacks cause far fewer sudden cardiac deaths than believed.
Otarmeni restores natural hearing in patients with OTOF gene mutations — and Regeneron will offer it free in the U.S.
Some Ozempic users report emotional flattening beyond food. Experts say it's rare but highlight the need for mental health support.
